MDXHEALTH (MDXH) Stock Fundamental Analysis

NASDAQ:MDXH • BE0974461940

3.61 USD
-0.02 (-0.55%)
Last: Feb 23, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall MDXH gets a fundamental rating of 3 out of 10. We evaluated MDXH against 521 industry peers in the Biotechnology industry. MDXH may be in some trouble as it scores bad on both profitability and health. MDXH is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year MDXH has reported negative net income.
  • In the past year MDXH has reported a negative cash flow from operations.
  • MDXH had negative earnings in each of the past 5 years.
  • In the past 5 years MDXH always reported negative operating cash flow.
MDXH Yearly Net Income VS EBIT VS OCF VS FCFMDXH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

  • With a decent Return On Assets value of -33.59%, MDXH is doing good in the industry, outperforming 63.53% of the companies in the same industry.
Industry RankSector Rank
ROA -33.59%
ROE N/A
ROIC N/A
ROA(3y)-31.55%
ROA(5y)-44.62%
ROE(3y)-441.71%
ROE(5y)-376.22%
ROIC(3y)N/A
ROIC(5y)N/A
MDXH Yearly ROA, ROE, ROICMDXH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

  • With an excellent Gross Margin value of 63.87%, MDXH belongs to the best of the industry, outperforming 80.04% of the companies in the same industry.
  • MDXH's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for MDXH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.87%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.37%
GM growth 5YN/A
MDXH Yearly Profit, Operating, Gross MarginsMDXH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • MDXH does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • MDXH has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for MDXH has been increased compared to 5 years ago.
  • MDXH has a worse debt/assets ratio than last year.
MDXH Yearly Shares OutstandingMDXH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
MDXH Yearly Total Debt VS Total AssetsMDXH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • MDXH has an Altman-Z score of -2.53. This is a bad value and indicates that MDXH is not financially healthy and even has some risk of bankruptcy.
  • MDXH has a Altman-Z score (-2.53) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.53
ROIC/WACCN/A
WACC8.97%
MDXH Yearly LT Debt VS Equity VS FCFMDXH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • MDXH has a Current Ratio of 1.14. This is a normal value and indicates that MDXH is financially healthy and should not expect problems in meeting its short term obligations.
  • MDXH has a Current ratio of 1.14. This is amonst the worse of the industry: MDXH underperforms 85.03% of its industry peers.
  • A Quick Ratio of 1.02 indicates that MDXH should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.02, MDXH is doing worse than 85.22% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.14
Quick Ratio 1.02
MDXH Yearly Current Assets VS Current LiabilitesMDXH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 57.89% over the past year.
  • The Revenue has grown by 21.62% in the past year. This is a very strong growth!
  • The Revenue has been growing by 50.17% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)57.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
Revenue 1Y (TTM)21.62%
Revenue growth 3Y59.39%
Revenue growth 5Y50.17%
Sales Q2Q%17.65%

3.2 Future

  • MDXH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.55% yearly.
  • MDXH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.31% yearly.
EPS Next Y53.68%
EPS Next 2Y32.43%
EPS Next 3Y27.55%
EPS Next 5YN/A
Revenue Next Year22.89%
Revenue Next 2Y22.93%
Revenue Next 3Y21.68%
Revenue Next 5Y21.31%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
MDXH Yearly Revenue VS EstimatesMDXH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M
MDXH Yearly EPS VS EstimatesMDXH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • MDXH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year MDXH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDXH Price Earnings VS Forward Price EarningsMDXH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDXH Per share dataMDXH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as MDXH's earnings are expected to grow with 27.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.43%
EPS Next 3Y27.55%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • MDXH does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MDXHEALTH

NASDAQ:MDXH (2/23/2026, 8:00:01 PM)

3.61

-0.02 (-0.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)02-26
Inst Owners46.53%
Inst Owner Change0%
Ins Owners6.67%
Ins Owner ChangeN/A
Market Cap98.51M
Revenue(TTM)150.68M
Net Income(TTM)-51.83M
Analysts86.67
Price Target7.18 (98.89%)
Short Float %0.12%
Short Ratio0.23
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-31.92%
Min EPS beat(2)-45.24%
Max EPS beat(2)-18.6%
EPS beat(4)1
Avg EPS beat(4)-19.65%
Min EPS beat(4)-45.24%
Max EPS beat(4)28.51%
EPS beat(8)1
Avg EPS beat(8)-53.52%
EPS beat(12)1
Avg EPS beat(12)-57.03%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.63%
Min Revenue beat(2)-4.38%
Max Revenue beat(2)-0.88%
Revenue beat(4)1
Avg Revenue beat(4)-0.62%
Min Revenue beat(4)-4.38%
Max Revenue beat(4)3.83%
Revenue beat(8)5
Avg Revenue beat(8)2.49%
Revenue beat(12)9
Avg Revenue beat(12)11.04%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-46.51%
EPS NY rev (1m)0%
EPS NY rev (3m)-15.33%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.65
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.64
EYN/A
EPS(NY)-0.31
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS5.52
BVpS-0.3
TBVpS-3.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -33.59%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.87%
FCFM N/A
ROA(3y)-31.55%
ROA(5y)-44.62%
ROE(3y)-441.71%
ROE(5y)-376.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.37%
GM growth 5YN/A
F-Score4
Asset Turnover0.98
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.45%
Cap/Sales 0.86%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.14
Quick Ratio 1.02
Altman-Z -2.53
F-Score4
WACC8.97%
ROIC/WACCN/A
Cap/Depr(3y)61.59%
Cap/Depr(5y)46.12%
Cap/Sales(3y)6.93%
Cap/Sales(5y)5.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
EPS Next Y53.68%
EPS Next 2Y32.43%
EPS Next 3Y27.55%
EPS Next 5YN/A
Revenue 1Y (TTM)21.62%
Revenue growth 3Y59.39%
Revenue growth 5Y50.17%
Sales Q2Q%17.65%
Revenue Next Year22.89%
Revenue Next 2Y22.93%
Revenue Next 3Y21.68%
Revenue Next 5Y21.31%
EBIT growth 1Y34.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year114.46%
EBIT Next 3Y46.08%
EBIT Next 5Y35.99%
FCF growth 1Y21.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.8%
OCF growth 3YN/A
OCF growth 5YN/A

MDXHEALTH / MDXH FAQ

Can you provide the ChartMill fundamental rating for MDXHEALTH?

ChartMill assigns a fundamental rating of 3 / 10 to MDXH.


What is the valuation status of MDXHEALTH (MDXH) stock?

ChartMill assigns a valuation rating of 1 / 10 to MDXHEALTH (MDXH). This can be considered as Overvalued.


How profitable is MDXHEALTH (MDXH) stock?

MDXHEALTH (MDXH) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for MDXH stock?

The Earnings per Share (EPS) of MDXHEALTH (MDXH) is expected to grow by 53.68% in the next year.